Aim: The increasing incidence and poor outcome associated with MPM requires to find effective treatment for this disease. PD1/PD-L1 pathway plays a central role in tumor immune evasion and appears to be predictive and prognostic marker. PD-L1 is expressed in many different human cancers but its role in MPM has yet to be established. The aim of this study is to evaluate the expression of PD-L1 in MPM Methods: 119 MPM patients (p) from Vall d'Hebron University Hospital and 12 Octubre University Hospital between November 2002 and February 2014 were reviewed. Formalin-fixed, paraffin-embedded tissue was stained with anti-PD-L1 (clone E1L3N) and intensity was scored as 0 (negative), 1 (weak), 2 (moderate) and 3 (strong). Cases showing more than 1% expression of PD-L1 were considered positive. Survival data were calculated by the Kaplan-Meier method. The associations of PD-L1 expression with outcome were assessed with Cox regression models. Results: Patient's characteristics: median age 69 years (42-90 years), males: 71.4%, PS 1:64.9%, asbestos exposure: 45%, stage III: 39%, epithelial subtype: 65.5%. PD-L1 was analyzed in 77 p and was positive in 20.7% p (14 samples in membrane, 16 in cytoplasm and 2 in immune infiltrate). PD-L1 intensity was weak in 56.2%, moderate in 25% and strong in 18.7% p. There was no significant relationship between PD-L1 expression and gender, smoking status, asbestos exposure, stage, and lymphocytic infiltration between PD-L1 positive and negative. We found differences in expression PD-L1 according to histology: PD-L1 expression was more frequent in no-epithelial tumor, 60% v 15% in epithelial; p = 0.033. The median survival in all population was 13.8 months, and for PD-L1 analysis patients, median survival in p PD-L1 positive was 4.79 vs 16.3 months in p PD-L1 negative (p = 0.012). Conclusions: We have shown PD-L1 is expressed in 20% of p and is a prognostic marker in MPM. Our results suggest PD-L1 warrants further exploration in selecting p for immunotherapy Disclosure: All authors have declared no conflicts of interest.
CITATION STYLE
Cedres, S., Ponce Aix, S., Zugazagoitia, J., Anguita, A. B., Sansano, I., Navarro Mendivil, A., … Felip, E. (2014). Analysis of Expression of Programmed Cell Death 1 Ligand 1 (Pd-L1) in Malignant Pleural Mesothelioma (Mpm). Annals of Oncology, 25, v1. https://doi.org/10.1093/annonc/mdu438.66
Mendeley helps you to discover research relevant for your work.